Smart Syringes Market to Reach USD 24.37 Billion by 2033, Growing at a CAGR of 10.6% | Astute Analytica

January 18, 2025 03:00 AM AEDT | By EIN Presswire
 Smart Syringes Market to Reach USD 24.37 Billion by 2033, Growing at a CAGR of 10.6% | Astute Analytica
Image source: EIN Presswire
CHICAGO, NY, UNITED STATES, January 17, 2025 /EINPresswire.com/ -- The global 𝐬𝐦𝐚𝐫𝐭 𝐬𝐲𝐫𝐢𝐧𝐠𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭, valued at 𝐔𝐒𝐃 𝟏𝟎.𝟐𝟐 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟒 is set to experience robust growth over the forecast period 𝟐𝟎𝟐𝟓–𝟐𝟎𝟑𝟑, achieving a projected valuation of 𝐔𝐒𝐃 𝟐𝟒.𝟑𝟕 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟑. This remarkable growth corresponds to a compound annual growth rate (𝐂𝐀𝐆𝐑) 𝐨𝐟 𝟏𝟎.𝟔%, driven by increasing adoption of advanced medical technologies and a growing focus on patient safety.

𝐓𝐡𝐞 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:- https://www.astuteanalytica.com/request-sample/smart-syringes-market

Smart syringes, designed to prevent reuse and reduce needlestick injuries, are gaining significant traction across healthcare settings. Rising awareness about infection control, coupled with stringent government regulations to enhance safety standards, is accelerating market adoption globally.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬

𝐃𝐫𝐢𝐯𝐞𝐫: 𝐒𝐨𝐚𝐫𝐢𝐧𝐠 𝐝𝐞𝐦𝐚𝐧𝐝 𝐟𝐨𝐫 𝐩𝐫𝐞𝐜𝐢𝐬𝐞 𝐢𝐧𝐬𝐮𝐥𝐢𝐧 𝐝𝐨𝐬𝐢𝐧𝐠 𝐰𝐢𝐭𝐡𝐢𝐧 𝐞𝐯𝐨𝐥𝐯𝐢𝐧𝐠 𝐝𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐬 𝐚𝐜𝐫𝐨𝐬𝐬 𝐯𝐚𝐫𝐢𝐞𝐝 𝐠𝐞𝐨𝐠𝐫𝐚𝐩𝐡𝐢𝐞𝐬

The increasing need for accurate insulin delivery is transforming how patients, healthcare providers, and manufacturers approach diabetes treatments. According to the IDF, the global population requiring insulin therapy now surpasses 35 million people who administer injections daily. Additionally, the American Diabetes Association records over 1.4 million annual new diagnoses in the US alone, meaning a sustained influx of patients requiring safe, efficient injection options As a result, the smart syringes market is witnessing a significant influx of demand. The WHO points out that more than 60% of diabetic complications stem from suboptimal medication adherence, prompting a surge of interest in smart syringes that provide integrated dose monitoring. In 2023, the CDC noted that mobile health applications synchronized with smart injection devices are being used by 2.6 million individuals in North America for better glycemic control. Pharmaceutical giants are also launching pilot programs in which 18 teaching hospitals across Europe test smart syringe feedback mechanisms for insulin drawing accuracy.

This surging demand in the smart syringes market is fueled by the growing complexity of diabetes regimens, where real-time data is crucial to prevent adverse events. Medical journals report that a single misdose among type 1 diabetics can result in serious complications if not swiftly corrected, reinforcing the necessity of precise injection delivery. Healthcare systems in major diabetic markets, including China and India, are scaling up advanced insulin therapy training, leading to nationwide campaigns promoting device literacy for 50 million newly diagnosed patients. Clinicians in these regions are increasingly prescribing smart syringes that log dose history automatically, ensuring immediate detection of errors. Such expansions not only alleviate clinical burdens but also empower patients through streamlined data-sharing with medical professionals—creating a robust push toward advanced injection systems worldwide.

𝐓𝐨𝐩 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐒𝐦𝐚𝐫𝐭 𝐒𝐲𝐫𝐢𝐧𝐠𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭

• Becton, Dickinson and Company
• Medtronic
• Terumo Corporation
• Gerresheimer AG
• Baxter
• Cardinal Health
• Parker Hannifin Corp.
• Numedico Technologies Pty Ltd
• Retractable Technologies, Inc.
• Smiths Group Plc
• Braun Melsungen AG
• Unilife Corporation
• Other Prominent Players

𝐅𝐨𝐫 𝐟𝐮𝐫𝐭𝐡𝐞𝐫 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐢𝐧𝐭𝐨 𝐭𝐡𝐞 𝐬𝐦𝐚𝐫𝐭 𝐬𝐲𝐫𝐢𝐧𝐠𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭, 𝐢𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠 𝐝𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐨𝐟 𝐭𝐫𝐞𝐧𝐝𝐬 𝐚𝐧𝐝 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬, 𝐩𝐥𝐞𝐚𝐬𝐞 𝐜𝐨𝐧𝐭𝐚𝐜𝐭: https://www.astuteanalytica.com/industry-report/smart-syringes-market

𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:

𝐁𝐲 𝐏𝐫𝐨𝐝𝐮𝐜𝐭

• Auto Disable Syringes
• Passive Safety Syringes
• Active Safety Syringes

𝐁𝐲 𝐀𝐠𝐞 𝐆𝐫𝐨𝐮𝐩

• Adults
• Pediatrics

𝐁𝐲 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧

• Vaccination
• Drug Delivery
• Blood Specimen Collection

𝐁𝐲 𝐄𝐧𝐝 𝐮𝐬𝐞𝐫

• Hospitals
• Psychiatrics
• Family Practices
• Diabetic Patients
• Others

𝐁𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥

• Direct Sales
• Online Sales
• Retail Pharmacies & Drug Stores
• Hospital & Clinic Purchases

𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa
• Saudi Arabia
• South Africa
• UAE
• Rest of MEA
• South America
• Argentina
• Brazil
• Rest of South America

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭@- https://www.astuteanalytica.com/request-sample/smart-syringes-market

𝐀𝐛𝐨𝐮𝐭 𝐀𝐬𝐭𝐮𝐭𝐞 𝐀𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyse for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Aamir Beg
Astute Analytica
+1 888-429-6757
email us here
Visit us on social media:
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.